2 months Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk Investor's Business Daily
Allurion catapulted Friday after the company said it plans to test its weight-loss technology with an obesity drug.
The post Allurion Catapults 132% On Its Plans To Outdo Eli Lilly, Novo Nordisk appeared first on Investor's Business Daily.